Anagrelide: very high response rate - Anagrelide Study Group Newsletter Article 17 February 2013 Pages: 6 - 6
Selective use of low osmolar contrast agents - the key to cost-effectiveness Newsletter Article 17 February 2013 Pages: 8 - 8
Equivalent cost/benefit ratios for mupirocin and erythromycin Newsletter Article 17 February 2013 Pages: 8 - 9
Improving antineoplastic regimens: the prognosis in cancer is looking better Newsletter Article 17 February 2013 Pages: 12 - 12
Gemfibrozil responses - effects of dosage and patient characteristics Newsletter Article 17 February 2013 Pages: 13 - 13
Flumazenil; an innovative agent for benzodiazepine-induced CNS depression Newsletter Article 17 February 2013 Pages: 13 - 13
Its not vaccine failure - but failure to vaccinate Newsletter Article 17 February 2013 Pages: 16 - 16
The risk of haemolysis may be overestimated in G6PD deficiency Newsletter Article 17 February 2013 Pages: 17 - 17
Fatal ‘Augmentin’-induced cholestatic hepatitis: first report Newsletter Article 17 February 2013 Pages: 18 - 18
Dexrazoxane ameliorates doxorubicin cardiotoxicity Newsletter Article 17 February 2013 Pages: 19 - 19
Resistance to aminoglycosides does not appear to be on the increase Newsletter Article 17 February 2013 Pages: 20 - 20
TNF alpha: important therapeutic implications in RDS Newsletter Article 17 February 2013 Pages: 20 - 20